Compounds > arginine

arginine and pirarubicin

arginine has been researched along with pirarubicin in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (25.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agata, N; Hara, Y; Hirano, S; Iguchi, H; Shirai, M; Tone, H; Urakawa, N1
Chytil, P; Etrych, T; Fang, J; Islam, W; Kusakabe, K; Maeda, H; Sakoguchi, A; Ulbrich, K1
Etrych, T; Fang, J; Imamura, T; Islam, W; Maeda, H; Subr, V; Ulbrich, K1
Ba, Y; Hou, Y; Wang, HQ1

Other Studies

4 other study(ies) available for arginine and pirarubicin

ArticleYear
Pirarubicin-induced endothelium-dependent relaxation in rat isolated aorta.
    The Journal of pharmacy and pharmacology, 1991, Volume: 43, Issue:12

    Topics: Animals; Aorta, Thoracic; Arginine; Doxorubicin; Endothelium, Vascular; In Vitro Techniques; Male; Muscle Contraction; Muscle Relaxation; Muscle, Smooth, Vascular; Nitric Oxide; Nitroarginine; Norepinephrine; Potassium Chloride; Rats; Rats, Inbred Strains; Superoxide Dismutase

1991
HPMA copolymer conjugate with pirarubicin: In vitro and ex vivo stability and drug release study.
    International journal of pharmaceutics, 2018, Jan-30, Volume: 536, Issue:1

    Topics: Animals; Antineoplastic Agents; Arginine; Doxorubicin; Drug Carriers; Drug Liberation; Humans; Methacrylates; Mice; Pilot Projects; Polymers; Rabbits; Rats; Serum Albumin, Bovine; Solubility

2018
Augmentation of the Enhanced Permeability and Retention Effect with Nitric Oxide-Generating Agents Improves the Therapeutic Effects of Nanomedicines.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:12

    Topics: Animals; Antineoplastic Agents; Arginine; Disease Models, Animal; Doxorubicin; Female; Hydroxyurea; Macromolecular Substances; Male; Mice; Nanomedicine; Nanoparticles; Neoplasms; Nitric Oxide; Nitric Oxide Donors; Nitroglycerin; Permeability; Rats, Sprague-Dawley

2018
Comparison on therapeutic effects of RFT and RCTVP regimen in the treatment of patients with indolent B-cell lymphoma in China.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Humans; Lymphoma, B-Cell; Male; Middle Aged; Prednisolone; Rituximab; Teniposide; Vidarabine

2012